Literature DB >> 24854900

Incidence for progression of hypervascular HCC in hypovascular hepatic nodules showing hyperintensity on gadoxetic acid-enhanced hepatobiliary phase in patients with chronic liver diseases.

Megumi Matsuda1, Takaharu Tsuda, Shinji Yoshioka, Shigetoshi Murata, Hiroaki Tanaka, Masashi Hirooka, Yoichi Hiasa, Teruhito Mochizuki.   

Abstract

PURPOSE: The purpose of this study was to elucidate the incidence and risk factors for the progression of hyperintense nodules, observed in the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA-enhanced MRI), to hypervascular hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: Hypovascular nodules (n = 157) showing hyperintensity in the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI were examined in 41 patients. All patients underwent computed tomography (CT) during hepatic arteriography and CT during arterial portography within one month of Gd-EOB-DTPA-enhanced MRI. The incidence of progression to hypervascular or classical HCC was calculated using the Kaplan-Meier method.
RESULTS: Tumor size was determined by univariate and multivariate analysis to be an important risk factor of hypervascularization (p = 0.041, odds ratio 1.135). The cumulative incidences of hypervascularization in hypovascular nodules showing hyperintensity on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI were 2.4, 4.5, and 6.2 % at 12, 24, and 36 months, respectively. The incidence of hypervascularization was significantly increased in nodules >10 mm in diameter (p = 0.00035).
CONCLUSION: In patients with chronic liver disease, hypovascular nodules presenting as hyperintense in the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI and >10 mm in diameter have malignant potential for progression to hypervascular HCC and require careful management.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24854900     DOI: 10.1007/s11604-014-0323-z

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  32 in total

1.  Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings.

Authors:  M Kadoya; O Matsui; T Takashima; A Nonomura
Journal:  Radiology       Date:  1992-06       Impact factor: 11.105

Review 2.  Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver.

Authors:  Irene Cruite; Michael Schroeder; Elmar M Merkle; Claude B Sirlin
Journal:  AJR Am J Roentgenol       Date:  2010-07       Impact factor: 3.959

3.  Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase.

Authors:  Kazuhiro Saito; Fumio Kotake; Naoki Ito; Taizo Ozuki; Ryuji Mikami; Kimihiko Abe; Yoko Shimazaki
Journal:  Magn Reson Med Sci       Date:  2005       Impact factor: 2.471

4.  Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow.

Authors:  Sachiyo Kogita; Yasuharu Imai; Masahiro Okada; Tonsok Kim; Hiromitsu Onishi; Manabu Takamura; Kazuto Fukuda; Takumi Igura; Yoshiyuki Sawai; Osakuni Morimoto; Masatoshi Hori; Hiroaki Nagano; Kenichi Wakasa; Norio Hayashi; Takamichi Murakami
Journal:  Eur Radiol       Date:  2010-05-19       Impact factor: 5.315

5.  Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features.

Authors:  Azusa Kitao; Yoh Zen; Osamu Matsui; Toshifumi Gabata; Satoshi Kobayashi; Wataru Koda; Kazuto Kozaka; Norihide Yoneda; Tatsuya Yamashita; Shuichi Kaneko; Yasuni Nakanuma
Journal:  Radiology       Date:  2010-07-27       Impact factor: 11.105

6.  Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA.

Authors:  Bernd B Frericks; Christoph Loddenkemper; Alexander Huppertz; Steffi Valdeig; Andrea Stroux; Marion Seja; Karl-Jürgen Wolf; Thomas Albrecht
Journal:  AJR Am J Roentgenol       Date:  2009-10       Impact factor: 3.959

7.  Detection of hypervascular malignant foci in borderline lesions of hepatocellular carcinoma: comparison of dynamic multi-detector row CT, dynamic MR imaging and superparamagnetic iron oxide-enhanced MR imaging.

Authors:  Rieko Shinmura; Osamu Matsui; Masumi Kadoya; Satoshi Kobayashi; Noboru Terayama; Junichiro Sanada; Hiroshi Demachi; Toshifumi Gabata
Journal:  Eur Radiol       Date:  2008-04-02       Impact factor: 5.315

8.  Early hepatocellular carcinomas showing isointensity or hyperintensity in gadoxetic acid-enhanced, hepatocyte-phase magnetic resonance images.

Authors:  Ningxin Chen; Utaroh Motosugi; Katsuhiro Sano; Tomoaki Ichikawa; Masayuki Nakano; Hiroyuki Morisaka; Shintaro Ichikawa; Masanori Matsuda; Hideki Fujii; Nobuyuki Enomoto; Tsutomu Araki
Journal:  J Comput Assist Tomogr       Date:  2013 May-Jun       Impact factor: 1.826

9.  Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.

Authors:  Seong Hyun Kim; Seung Hoon Kim; Jongmee Lee; Min Ju Kim; Yong Hwan Jeon; Yulri Park; Dongil Choi; Won Jae Lee; Hyo K Lim
Journal:  AJR Am J Roentgenol       Date:  2009-06       Impact factor: 3.959

10.  A comparison of hepatopathologists' and community pathologists' review of liver biopsy specimens from patients with hepatitis C.

Authors:  Maire Robert; Andre N Sofair; Ann Thomas; Beth Bell; Stephanie Bialek; Christopher Corless; Grace Van Ness; Sharon Huie-White; Nicole Stabach; Atif Zaman
Journal:  Clin Gastroenterol Hepatol       Date:  2008-12-13       Impact factor: 11.382

View more
  8 in total

Review 1.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

2.  Breakthrough Imaging in Hepatocellular Carcinoma.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

Review 3.  Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI.

Authors:  Ijin Joo; Jeong Min Lee
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

4.  Validation trial for efficacy of ultrasonographic measurement method to predict ascitic volume using virtual ultrasonography.

Authors:  Masashi Hirooka; Yohei Koizumi; Yusuke Imai; Atsushi Yukimoto; Takao Watanabe; Osamu Yoshida; Masanori Abe; Yoichi Hiasa
Journal:  J Med Ultrason (2001)       Date:  2018-04-18       Impact factor: 1.314

Review 5.  Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

Review 6.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

7.  Multiparametric imaging for detection and characterization of hepatocellular carcinoma using gadoxetic acid-enhanced MRI and perfusion-CT: which parameters work best?

Authors:  Mustafa Kurucay; Christopher Kloth; Sascha Kaufmann; Konstantin Nikolaou; Hans Bösmüller; Marius Horger; Wolfgang M Thaiss
Journal:  Cancer Imaging       Date:  2017-06-28       Impact factor: 3.909

8.  Usefulness of a New Three-Dimensional Simulator System for Radiofrequency Ablation.

Authors:  Masashi Hirooka; Yohei Koizumi; Yusuke Imai; Teruki Miyake; Takao Watanabe; Osamu Yoshida; Eiji Takeshita; Yoshio Tokumoto; Masanori Abe; Yoichi Hiasa
Journal:  PLoS One       Date:  2016-02-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.